Biovail sentenced in US kickback scheme, formalising a 2008 agreement
This article was originally published in Scrip
Executive Summary
Biovail's US subsidiary pleaded guilty to conspiracy and kickback charges and has been sentenced to pay a criminal fine of $22.2 million in connection with a previously disclosed US scheme whereby it paid doctors kickbacks to prescribe Cardizem LA (diltiazem HCl extended-release). The company will also pay a $2.4 million civil penalty, which will end the case, the government said.